Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (12): 1628-1631.

• Viral Hepatitis • Previous Articles     Next Articles

The clinical significance of serum miR-625-5p levels in patients with chronic hepatitis B

CHU Li1, REN Chuan-lu1, DING Jun2, TANG Min3, CAI Dong-ping1, ZHOU Xin1   

  1. 1. Department of Laboratory, the 904th Hospital of the Joint Logistics Support Force, Wuxi 214044, China;
    2. Department of Urology, the 904th Hospital of the Joint Logistics Support Force, Wuxi 214044, China;
    3. Department of Respiratory, the 904th Hospital of the Joint Logistics Support Force, Wuxi 214044, China
  • Received:2025-04-30 Published:2026-02-10
  • Contact: ZHOU Xin,Email:shiningzhoux@126.com

PDF (PC)

1

Abstract: Objective To analyze the serum levels of miR-625-5p in patients with chronic hepatitis B viral (HBV) infection and explore its potential significance in clinical diagnosis and prognosis. Methods The study was conducted from February 2021 to February 2024, including 106 confirmed cases of chronic hepatitis B (CHB), with 93 healthy individuals serving as controls during the same period of time. The serum levels of miR-625-5p, liver function, and HBV viral load were measured using quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between miR-625-5p, liver function, and HBV viral load was investigated. The diagnostic values of miR-625-5p for liver inflammatory grading (G0~G4) and fibrosis staging (F0~F4) were assessed using the receiver operating characteristic (ROC) curve method. Results The values for miR-625-5p, ALT, AST levels in the control group were 1.03±0.15, (28.26±6.47) U/L, and (29.87±5.67) U/L, respectively, The values for miR-625-5p, ALT, AST levels, and HBV viral load were 0.89±0.16, (83.14±15.46) U/L, (58.36±12.41) U/L, and (10.09±3.62) IU/mL in the G0 group; 0.71±0.13, (99.57±19.82) U/L, (70.13±18.79) U/L, and (18.47±5.87) IU/mL in the G1~2 group; and 0.64±0.11, (118.41±29.59) U/L, (79.68±25.94) U/L, and (25.46±8.52) IU/mL in the G3~4 group. The differences of viral load among the groups were statistically significant (F=79.216, 337.692, 130.472, 48.862, P<0.05). There was a significant negative correlation between miR-625-5p, ALT, AST, and HBV viral load (r=-0.283, -0.212, -0.453, P<0.05). The levels of miR-625-5p, ALT, AST, and viral load were (0.92±0.21), (75.23±16.48)U/L, (63.17±16.46)U/L, and (8.76±4.89) IU/mL in patients with F0~1, and 0.68±0.17, (115.75±27.78) U/L, (74.82±23.67) U/L, and (23.79±9.33) IU/mL in patients with F2~4, respectively. The comparisons between these two groups had statistically significant differences (t=6.204, 7.675, 2.529, 8.600, P<0.05). The ROC curve evaluation of miR-625-5p for the diagnosis of liver fibrosis stages showed a sensitivity of 83.8%, a specificity of 68.7%, and an AUC of 0.806, indicating an high diagnostic value. Conclusion Low expression of miR-625-5p in patients with CHB was associated with liver inflammation and liver function impairment. Therefore, miR-625-5p could serve as a potential biomarker for CHB to assess disease’s activity and prognosis.

Key words: Chronic hepatitis B, miR-625-5p, Diagnosis, Prognosis, Disease activity